GLP-1 Diabetes

Semaglutide A1C Reduction: The Diabetes Trial Data

Semaglutide reduced A1C by 1.5-1.8% in SUSTAIN trials and 1.0-1.4% as oral Rybelsus in PIONEER trials. A review of all key trial results and what they mean.